Reversible peg-interferon-induced unilateral sensorineural hearing loss during hepatitis B treatment.
Salkic
Nermin
N
Zerem
Enver
E
Zildzic
Muharem
M
Basic
Mirela
M
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001299:Audiometry; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D006509:Hepatitis B / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects*; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000009:adverse effects*; D011994:Recombinant Proteins; D014803:Vitamin B Complex / Q000008:administration & dosage
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014803:Vitamin B Complex; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a